University of Liège Eubelius (Brussels)

Sandrine Mathieu

University of Liège, Eubelius (Brussels)
Associate

Sandrine Mathieu is an associate at Eubelius (Brussels bar). In addition, she is a teaching and research assistant in European Law at the University of Liège. Sandrine holds a Master’s degree in Law from the University of Liège (2014) and an LL.M in European Law from the College of Europe (2016).

Contact

Linked authors

International Center for Law & Economics (Portland)
United States 5 contributions 1531 visits
University of Liège
Belgium 390 contributions 668502 visits
University of Liège
Belgium 1 contribution 150 visits
University of Liège
Belgium 1 contribution 289 visits
University of Liège
Belgium 2 contributions 455 visits

Articles

788 Bulletin

Sandrine Mathieu, Guillaume Azevedo Mendes The Belgian Competition Authority rules that a national football association’s conditions to obtain a professional license are prima facie incompatible with competition law and orders interim measures (Virton / RBFA)

74

On 19 November 2020, the Belgian Competition Authority (“BCA”) ordered interim measures against the Royal Belgian Football Association (“RBFA”) following a request filed by the professional football club Royal Excelsior Virton (“RE Virton”). The BCA considered that the RBFA’s refusal to grant a (...)

Sandrine Mathieu, Thaiane Abreu The EU General Court confirms the Commission’s decision finding that the Lithuanian railway incumbent abused its dominant position by dismantling a rail track (Lietuvos geležinkelai)

181

Comment On 18 November 2020, the General Court of the European Union (‘GC’) delivered its ruling in the Lietuvos geležinkeliai [Lithuanian Railways] case and upheld the European Commission’s decision in which the national railway company of Lithuania was found to have abused its dominant position (...)

Amélie Lamarcq, Sandrine Mathieu The EU Court of Justice clarifies the conditions under which pay-for-delay agreements preventing generic versions of a patented medicine from entering the market or delaying such entry may constitute a restriction of competition "by object" or "by effect" as well as an abuse of dominant position (Generics - UK / GlaxoSmithKline / Actavis / Xellia Pharmaceuticals / Merck / Alpharma)

533

On 30 January 2020, the Court of Justice of the EU (‘CJEU’) ruled on the applicability of competition law to settlement agreements between a holder of a pharmaceutical patent and manufacturers of generic medicines. In a judgment issued only a week after Advocate General Kokott delivered her (...)

Send a message